Relevant bibliographies by topics / Pharmaceutical care

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Pharmaceutical care'

Author: Grafiati
Published: 4 June 2021
Last updated: 15 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical care.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical care"

1

Chrisp, Paul. "Pharmaceutical care." Inpharma Weekly &NA;, no. 894 (1993): 5–6. http://dx.doi.org/10.2165/00128413-199308940-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

KIELGAST, PETER J. "Pharmaceutical care." International Journal of Pharmacy Practice 2, no. 3 (1993): 125–26. http://dx.doi.org/10.1111/j.2042-7174.1993.tb00742.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hepler, Charles D. "Pharmaceutical care." Pharmacy World and Science 18, no. 6 (1996): 233–35. http://dx.doi.org/10.1007/bf00735965.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Allwood, M. C., C. L. Ronchera-Oms, T. Sizer, B. McElroy, and G. Hardy. "From pharmaceutics to pharmaceutical care in nutritional support." Clinical Nutrition 14, no. 1 (1995): 1–3. http://dx.doi.org/10.1016/s0261-5614(06)80002-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hopefl, Alan W. "Costs of Pharmaceutical Care: Can the Profession do Anything?" Annals of Pharmacotherapy 26, no. 12 (1992): 1585–88. http://dx.doi.org/10.1177/106002809202601219.

Full text
Abstract:
OBJECTIVE: To review some of the factors that influence the cost of pharmaceuticals and the delivery of pharmaceutical care as well as some possible measures for decreasing these costs. DATA SYNTHESIS: Clinical studies have been selected to illustrate factors that may add to the overall cost of pharmaceutical care. CONCLUSIONS: Because of the perceived problems resulting from the introduction of new, expensive pharmaceuticals, possible means of controlling the costs of individual products are discussed. In addition, recommendations for achieving cooperation between pharmaceutical manufacturers and pharmacy practitioners in demonstrating the cost-effectiveness of new products are provided.
APA, Harvard, Vancouver, ISO, and other styles
6

Laven, David L., and William B. Hladik. "Pharmaceutical Care and Diagnostic Pharmaceuticals: Patient Care Avenues Not to Be Overlooked." Journal of Pharmacy Practice 7, no. 3 (1994): 79–83. http://dx.doi.org/10.1177/089719009400700302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bomfim, José Henrique Gialongo Gonçales. "Pharmaceutical Care in Sports." Pharmacy 8, no. 4 (2020): 218. http://dx.doi.org/10.3390/pharmacy8040218.

Full text
Abstract:
Pharmaceutical care in sports is a new field of work to clinical pharmacists, focused on promoting pharmacotherapeutic follow up and clinical services to athletes, physical activity practitioners and enthusiasts of any sports modality. A broad range of pharmaceuticals, dietary supplements and herbal drugs have been used historically as performance promoters, doping or ergogenic aids. In this context, the role of pharmacists in prevent adverse events, drug interactions or any drug related problems, as doping issues, was described. Its actions can be important to contribute with a multi professional clinical health team, leading athletes to use these resources in a rational way, promoting and optimizing the therapeutic when its necessary.
APA, Harvard, Vancouver, ISO, and other styles
8

Manasse, Henri R. "The Care in Pharmaceutical Care." Journal of Pharmacy Teaching 3, no. 3 (1992): 39–52. http://dx.doi.org/10.1300/j060v03n03_06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hill, Peter. "Pharmaceutical care R.I.P?" International Journal of Pharmacy Practice 20, no. 1 (2012): 2–3. http://dx.doi.org/10.1111/j.2042-7174.2011.00184.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Morley, P. C. "Pharmaceutical care: desiderata." Journal of Clinical Pharmacy and Therapeutics 18, no. 3 (1993): 143–46. http://dx.doi.org/10.1111/j.1365-2710.1993.tb00604.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaceutical care"

1

Clifford, Rhonda Marise. "Pharmaceutical care in diabetes mellitus." Curtin University of Technology, School of Pharmacy, 2004. http://espace.library.curtin.edu.au:80/R/?func=dbin-jump-full&object_id=14951.

Full text
Abstract:
People with diabetes mellitus are more likely to die from cardiovascular causes than those without diabetes, and modifiable risk factors, such as hyperglycaemia, dyslipidaemia and hypertension can be targeted in intervention programs to decrease this risk. In addition to tertiary care for patients with diabetes, there is a need for simple programs to be implemented in the community that allow the benefits of improved metabolic and blood pressure control to be realised more widely. Pharmaceutical care comprises the detection, prevention and solution of drug-related problems in a quantifiable form, so that outcomes of care can be easily reviewed and monitored. Previous studies of pharmaceutical care programs in patients with diabetes do not provide conclusive evidence of the benefit of pharmaceutical care. The aim of this research was to evaluate the impact of the provision of pharmaceutical care to patients with diabetes mellitus in an Australian context. In order to develop a pharmaceutical care program, the characteristics of an Australian cohort of patients with diabetes were reviewed. The Fremantle Diabetes Study (FDS), was a community-based prospective observational study of diabetes care, control and complications in a postcode-defined region of 120 097 people surrounding the port city of Fremantle in Western Australia. It was intended that the FDS annual reviews would provide important local information in order to design and implement a prospective pharmaceutical care program. A pilot pharmaceutical care program was subsequently developed for use in a diabetes outpatient clinic. This program was then modified for use in a community-based sample of type 2 diabetes mellitus patients, drawn from the FDS cohort.<br>Demographic parameters, including ethnicity and treatment details, were reviewed at study entry for the full FDS cohort and then over time for a subset of patients that returned for four subsequent annual assessments. Insulin use was more common in patients of Southern European origin compared with the Anglo-Celt group irrespective of the level of glycaemia, at baseline. This difference persisted during subsequent follow-up but was not associated with improved glycaemic control. These findings demonstrated that there are important ethnic differences in the management of patients with type 2 diabetes mellitus. The pilot pharmaceutical care program was carried out in high-risk diabetes mellitus patients attending a hospital outpatient clinic. The patients had poor glycaemic control, dyslipidaemia, hypertension and/or were on three or more prescription medications. In the pharmaceutical care arm, a clinical pharmacist reviewed and monitored all aspects of the patients' drug therapy in collaboration with other health care professionals at six weekly intervals for six months. The control patients received usual outpatient care. Seventy-three patients were recruited into the study, of whom 48 (66%) were randomised to receive pharmaceutical care. One in six patients was taking complementary medicines. The pharmaceutical care program provided patients with important medication information that resulted in changes to drug therapy. However, the six-month program did not lead to an improvement in glycaemic control. The next phase of the study adapted the pilot hospital-based pharmaceutical care program to a community-based setting.<br>Two hundred and two type 2 diabetes mellitus FDS patients were recruited, of whom 101 (50%) were randomised to the pharmaceutical care program, and all were followed for 12-months. There were significant reductions in risk factors associated with coronary heart disease in the case but not the control group over time, specifically glycaemic control, lipid levels, and blood pressure. Glycosylated haemoglobin fell from 7.5% to 7.0% (P<0.0001), total cholesterol fell from 5 mmol/L to 4.6 mmol/L (P<0.0001), systolic blood pressure fell from 158 mmHg to 143 mmHg (P<0.0001) and diastolic blood pressure fell from 77mmHg to 71mmHg (P<0.0001). Multiple linear regression analysis confirmed that pharmaceutical care program involvement was an independent predictor of benefit after adjustment for key variables. The 10-year coronary heart disease risk for patients without a previous coronary event was reduced by 4.6% over the 12-month study period in the pharmaceutical care group (P<0.0001), while there was no change in the controls (P=0.23). This phase of the study showed that medium-term individualised pharmaceutical care reduced vascular risk factors in a community-based cohort of patients with diabetes and that provision of a multifactorial intervention can improve health outcomes in type 2 diabetes mellitus. As part of the pharmaceutical care program, a high level of complementary medicine use was found. As a result, a study of complementary medicine use was undertaken in 351 patients from the FDS. A convenience sample of FDS patients was interviewed regarding their use of complementary medicines. A literature search was conducted to assess the potential impact of these medicines on diabetes, concomitant medications or diabetes-related co-morbidities.<br>Eighty-three of 351 (23.6%) patients with diabetes had consumed at least one complementary medicine in the previous year and 42% (77/183) of the products potentially necessitated additional patient monitoring or could be considered potentially inappropriate for a diabetic patient. The data indicated the need for patient disclosure of complementary medicine use and adequate monitoring for complementary medicine-related adverse events, as part of the pharmaceutical care process. The pharmaceutical care model was established to provide a framework by which drug use could be improved to enhance patients' clinical and health-related quality of life outcomes. For the present study, a straightforward pharmaceutical care program was adapted from a hospital setting to a community setting, where the principal requirement was a clinical pharmacist who had completed a self-directed diabetes-training program. In this context, clinically relevant parameters improved over the course of the study period. Pharmaceutical care programs such as this can begin the process of translating the findings of large and expensive clinical trials into standard clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
2

Clifford, Rhonda. "Pharmaceutical care in diabetes mellitus." Thesis, Curtin University, 2004. http://hdl.handle.net/20.500.11937/1907.

Full text
Abstract:
People with diabetes mellitus are more likely to die from cardiovascular causes than those without diabetes, and modifiable risk factors, such as hyperglycaemia, dyslipidaemia and hypertension can be targeted in intervention programs to decrease this risk. In addition to tertiary care for patients with diabetes, there is a need for simple programs to be implemented in the community that allow the benefits of improved metabolic and blood pressure control to be realised more widely. Pharmaceutical care comprises the detection, prevention and solution of drug-related problems in a quantifiable form, so that outcomes of care can be easily reviewed and monitored. Previous studies of pharmaceutical care programs in patients with diabetes do not provide conclusive evidence of the benefit of pharmaceutical care. The aim of this research was to evaluate the impact of the provision of pharmaceutical care to patients with diabetes mellitus in an Australian context. In order to develop a pharmaceutical care program, the characteristics of an Australian cohort of patients with diabetes were reviewed. The Fremantle Diabetes Study (FDS), was a community-based prospective observational study of diabetes care, control and complications in a postcode-defined region of 120 097 people surrounding the port city of Fremantle in Western Australia. It was intended that the FDS annual reviews would provide important local information in order to design and implement a prospective pharmaceutical care program. A pilot pharmaceutical care program was subsequently developed for use in a diabetes outpatient clinic. This program was then modified for use in a community-based sample of type 2 diabetes mellitus patients, drawn from the FDS cohort.Demographic parameters, including ethnicity and treatment details, were reviewed at study entry for the full FDS cohort and then over time for a subset of patients that returned for four subsequent annual assessments. Insulin use was more common in patients of Southern European origin compared with the Anglo-Celt group irrespective of the level of glycaemia, at baseline. This difference persisted during subsequent follow-up but was not associated with improved glycaemic control. These findings demonstrated that there are important ethnic differences in the management of patients with type 2 diabetes mellitus. The pilot pharmaceutical care program was carried out in high-risk diabetes mellitus patients attending a hospital outpatient clinic. The patients had poor glycaemic control, dyslipidaemia, hypertension and/or were on three or more prescription medications. In the pharmaceutical care arm, a clinical pharmacist reviewed and monitored all aspects of the patients' drug therapy in collaboration with other health care professionals at six weekly intervals for six months. The control patients received usual outpatient care. Seventy-three patients were recruited into the study, of whom 48 (66%) were randomised to receive pharmaceutical care. One in six patients was taking complementary medicines. The pharmaceutical care program provided patients with important medication information that resulted in changes to drug therapy. However, the six-month program did not lead to an improvement in glycaemic control. The next phase of the study adapted the pilot hospital-based pharmaceutical care program to a community-based setting.Two hundred and two type 2 diabetes mellitus FDS patients were recruited, of whom 101 (50%) were randomised to the pharmaceutical care program, and all were followed for 12-months. There were significant reductions in risk factors associated with coronary heart disease in the case but not the control group over time, specifically glycaemic control, lipid levels, and blood pressure. Glycosylated haemoglobin fell from 7.5% to 7.0% (P<0.0001), total cholesterol fell from 5 mmol/L to 4.6 mmol/L (P<0.0001), systolic blood pressure fell from 158 mmHg to 143 mmHg (P<0.0001) and diastolic blood pressure fell from 77mmHg to 71mmHg (P<0.0001). Multiple linear regression analysis confirmed that pharmaceutical care program involvement was an independent predictor of benefit after adjustment for key variables. The 10-year coronary heart disease risk for patients without a previous coronary event was reduced by 4.6% over the 12-month study period in the pharmaceutical care group (P<0.0001), while there was no change in the controls (P=0.23). This phase of the study showed that medium-term individualised pharmaceutical care reduced vascular risk factors in a community-based cohort of patients with diabetes and that provision of a multifactorial intervention can improve health outcomes in type 2 diabetes mellitus. As part of the pharmaceutical care program, a high level of complementary medicine use was found. As a result, a study of complementary medicine use was undertaken in 351 patients from the FDS. A convenience sample of FDS patients was interviewed regarding their use of complementary medicines. A literature search was conducted to assess the potential impact of these medicines on diabetes, concomitant medications or diabetes-related co-morbidities.Eighty-three of 351 (23.6%) patients with diabetes had consumed at least one complementary medicine in the previous year and 42% (77/183) of the products potentially necessitated additional patient monitoring or could be considered potentially inappropriate for a diabetic patient. The data indicated the need for patient disclosure of complementary medicine use and adequate monitoring for complementary medicine-related adverse events, as part of the pharmaceutical care process. The pharmaceutical care model was established to provide a framework by which drug use could be improved to enhance patients' clinical and health-related quality of life outcomes. For the present study, a straightforward pharmaceutical care program was adapted from a hospital setting to a community setting, where the principal requirement was a clinical pharmacist who had completed a self-directed diabetes-training program. In this context, clinically relevant parameters improved over the course of the study period. Pharmaceutical care programs such as this can begin the process of translating the findings of large and expensive clinical trials into standard clinical practice.
APA, Harvard, Vancouver, ISO, and other styles
3

Al, Mazroui Nadia. "Pharmaceutical care of type 2 diabetic patients." Thesis, Queen's University Belfast, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.431401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bronkhorst, Elmien. "An Assessment of the need of pharmaceutical services in the intensive care unit and high care unit of Steve Biko Academic hospital." Thesis, University of Limpopo (Medunsa Campus), 2012. http://hdl.handle.net/10386/1081.

Full text
Abstract:
Thesis (MSc(Med)(Pharmacy)) -- University of Limpopo, 2012.<br>The role of the pharmacist has evolved over the last two decades beyond the traditional functions of dispensing and stock control. The focus has shifted toward patient-oriented functions, in which the pharmacist assumes responsibility for the patient’s drug- and healthcare needs as well as the outcome of treatment. The aim of this research was to assess the need for pharmaceutical care to the Surgical Intensive Care Unit of Steve Biko Hospital. The surgical and trauma ICU is a 12 bed unit to which the researcher rendered pharmaceutical care over an eight week period, from 14 February to 26 March 2011. Interventions to assess drug therapy and achieve definite outcomes to improve patients’ quality of life were documented for 51 study patients according to the system developed by the American Society of Health-System Pharmacists (1992). Of the 51 patients, 35 were male and 16 were female. The age of the patients ranged from 12 years to 86 years, with most patients admitted to the unit in the age groups 21 to 30 years, and 51 to 60 years. The patients’ estimated weights ranged from 40kg to 120kg with older patients, from age 41 upwards, weighing more. The average stay in the unit was 8.7 days, with the minimum stay for one patient being only one day, and the maximum stay for one patient was 26 days. In the study, the HIV status of only 13 of the 51 patients was tested. Of the 13 patients, six were HIV positive, while seven tested negative. All the patients admitted to the unit were not tested for HIV, because they were not admitted to the unit for HIV-related causes, and test results would not have had an effect on their outcome. Diagnoses encountered most frequently in the unit were trauma (21 patients), skeletal involvement or fractures (16 patients), infections or sepsis (15 patients) and gastro-intestinal bleeds (14 patients). In most cases more than one diagnosis applied to the same patient, since patients admitted with trauma also had skeletal or gastro-intestinal involvement. An Assessment of the need of Pharmaceutical Services in the Intensive Care Unit and High Care Unit of Steve Biko Academic Hospital viii The medications prescribed most frequently were enoxaparin (49 patients), sucralfate (41 patients) and multivitamin syrup (47 patients); in accordance with the standard ward protocol for prophylactic regimens. The drug class most often used was the anti-infectiveshaving124 items prescribed during the study period. Of these, the broad spectrum antibiotics were used most frequently, e.g. piperacillin/tazobactam (22 patients), meropenem (11 patients) and imipenem (11 patients). An average of 12 medications was prescribed for each patient in the ward. A total of 181 interventions were suggested for the 51 patients during the study period, of which 127 (70%) were accepted and implemented by the medical and nursing staff. The average number of interventions per patient ranged from 0 to 13 with a median of 3.5 interventions per patient. The four most frequent problem types were untreated medical conditions (15.5%), length or course of therapy inappropriate (13.8%), investigations indicated or outstanding (12.2%) and prescribed doses and dosing frequency appropriate (11%). Interventions were also made regularly to address system errors or non-compliance and factors hindering achievement of therapeutic effect. The perceived need for pharmaceutical care by healthcare professionals in the SICU was measured by questionnaires before and after the study period. The feedback by staff regarding the pharmacist working in the ward was very positive. They appreciated the researchers input on ward rounds, as well as assistance with problems encountered with the pharmacy. Of the total time spent in the ward, the researcher spent 28% of her time on patient evaluation. Ward rounds also took up a great deal of time (21.7%), since ward rounds were done with different members of the multidisciplinary team. Most interventions were suggested during ward rounds. The costs saved during the study period were enough to justify the appointment of a pharmacist to the ward on a permanent basis, albeit for limited hours daily. The researcher designed an antibiotic protocol for the unit. The protocol was designed according to international standards, and after discussion with the microbiologists, adapted for use in the specific unit. An Assessment of the need of Pharmaceutical Services in the Intensive Care Unit and High Care Unit of Steve Biko Academic Hospital ix In conclusion, the study results have demonstrated that a pharmacist’s contribution to patient care at ward level in a surgical ICU resulted in clinical outcomes that improved the patient’s quality of life. Drug-related problems were identified and addressed. Medical staff in the S-ICU accepted the pharmacist’s interventions and even welcomed her contribution to other ward functions, for instance managing medication and providing education. Pharmaceutical care should be rendered on a permanent basis to the Surgical ICU and the pharmacist should increasingly become a key part of the multidisciplinary team, taking responsibility for patients’ medication needs.
APA, Harvard, Vancouver, ISO, and other styles
5

Varma, Sumanthra. "Pharmaceutical care of elderly congestive heart failure patients." Thesis, Queen's University Belfast, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.388199.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sturgess, Ian K. "Pharmaceutical care provision to community dwelling elderly patients." Thesis, Queen's University Belfast, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.268313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sadik, A. S. "Pharmaceutical care of patients with congestive heart failure." Thesis, Queen's University Belfast, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.269178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Scanlan, Justine Claire. "Pharmaceutical care for cancer patients : a multidisciplinary approach." Thesis, University College London (University of London), 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.289814.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stern, Philip. "Patterns of pharmaceutical prescribing." Thesis, London Business School (University of London), 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.309363.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Glynn, Caroline. "Aspects of pharmaceutical care provision by the community pharmacist." Thesis, Queen's University Belfast, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.337033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Pharmaceutical care"

1

Penna, Richard P., and Calvin H. Knowlton. Pharmaceutical care. 2nd ed. American Society of Health-System Pharmacists, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

1949-, Knowlton Calvin H., and Penna Richard P, eds. Pharmaceutical care. Chapman & Hall, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

M, Strand Linda, and Morley Peter C, eds. Pharmaceutical care practice. McGraw-Hill, Health Professions Division, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

J, Cipolle Robert, Morley Peter C, and Cipolle Robert J, eds. Pharmaceutical care practice. 3rd ed. McGraw-Hill, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Marie, Haddad Amy, and Buerki Robert A, eds. Ethical dimensions of pharmaceutical care. Pharmaceutical Products Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Angela, Kim-Sing, and Canadian Society of Hospital Pharmacists., eds. Direct patient care curriculum: Pharmaceutical care education modules. Canadian Society of Hospital Pharmacists, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

N, Tindall William, and Millonig Marsha K, eds. Pharmaceutical care: Insights from community pharmacists. CRC Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Galt, Kimberly A. Clinical skills program: Advancing pharmaceutical care. American Society of Hospital Pharmacists, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

P, Rovers John, and American Pharmaceutical Association, eds. A practical guide to pharmaceutical care. 2nd ed. American Pharmaceutical Association, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

P, Rovers John, ed. A practical guide to pharmaceutical care. American Pharmaceutical Association, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Pharmaceutical care"

1

Al-Worafi, Yaser Mohammed. "Pharmaceutical Care." In Handbook of Medical and Health Sciences in Developing Countries. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-030-74786-2_260-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Westerlund, Tommy. "Documenting Pharmaceutical Care." In The Pharmacist Guide to Implementing Pharmaceutical Care. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92576-9_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Khatri, Naresh. "Pharmaceutical Companies." In Crony Capitalism in US Health Care. Routledge, 2021. http://dx.doi.org/10.4324/9781003112204-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Alves da Costa, Filipa. "Pharmaceutical Care in Europe." In The Pharmacist Guide to Implementing Pharmaceutical Care. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92576-9_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lee, Shaun Wen Huey, and J. Simon Bell. "Pharmaceutical Care in Asia." In The Pharmacist Guide to Implementing Pharmaceutical Care. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92576-9_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Moles, Rebekah, and Stephen Carter. "Pharmaceutical Care in Pediatrics." In The Pharmacist Guide to Implementing Pharmaceutical Care. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92576-9_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Alves da Costa, Filipa, and Kurt E. Hersberger. "Paying for Pharmaceutical Care." In The Pharmacist Guide to Implementing Pharmaceutical Care. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92576-9_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Marinkovic, Valentina, Marina Odalovic, Ivana Tadic, Dusanka Krajnovic, Irina Mandic, and Heather L. Rogers. "Person-Centred Care Interventions in Pharmaceutical Care." In Intelligent Systems for Sustainable Person-Centered Healthcare. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-79353-1_4.

Full text
Abstract:
AbstractThis chapter is divided into four sections. The first section introduces the concept of person-centred care within pharmaceutical care delivery and provides a historical context. The second section focuses on the professionals and explores the role of person-centred pharmaceutical care as part of multi-disciplinary health services delivery teams. The third section focuses on the patient and describes the role of health literacy in the implementation of person-centred pharmaceutical care. The last section examines E-pharmacy services and the implementation of telepharmacy with implications for person-centred care.
APA, Harvard, Vancouver, ISO, and other styles
9

Abbott, Thomas A. "Regulating Pharmaceutical Prices." In Health Care Policy and Regulation. Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-2219-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nahler, Gerhard. "health care expenditure." In Dictionary of Pharmaceutical Medicine. Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_634.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical care"

1

Dou, Yutao, Zike Deng, Tao Xing, Jian Xiao, and Shaoliang Peng. "Autonomous Pharmaceutical Care with Large Language Models." In 2024 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2024. https://doi.org/10.1109/bibm62325.2024.10822302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

del Pozo-Rodríguez, Ana, Arantxa Isla, Begoña Calvo, Alicia Rodríguez-Gascón, and María Ángeles Solinís. "SERVICE-LEARNING IN THE FIELD OF PHARMACEUTICAL CARE AND SOCIAL PHARMACY AS A TRAINING TOOL TO DEVELOP THE FINAL DEGREE PROJECT." In 17th annual International Conference of Education, Research and Innovation. IATED, 2024. https://doi.org/10.21125/iceri.2024.1324.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sibychan, Jerrin Job, Nicola Sorace, Jason Melnick, et al. "Use of Discrete Element Method to Troubleshoot Aesthetic Defects in Pharmaceutical Tablets." In Foundations of Computer-Aided Process Design. PSE Press, 2024. http://dx.doi.org/10.69997/sct.148066.

Full text
Abstract:
Pharmaceutically elegant tablets are an expectation from pharmacists, health care providers and consumers for solid oral dosage forms. The presence of non-aesthetically pleasing defects in solid oral dosage forms can result in complaints back to the manufacturer and potentially non-compliance with medicines. The purpose of this study was to simulate and analyze the design of a tablet core and the aqueous film-coating process, to gain a better understanding of tablet defect generation, and to help eliminate the defects from the finished product. This evaluation employs Discrete Element Method (DEM) using the software product Altair� EDEM� to understand the potential mechanisms that are causing the defects, based on the forces tablets experience in the coating operation, along with the number of tablet-to-tablet interactions that occur during the duration of the process. Defects observed during the scale up of the coating process to a commercial production scale confirmed the DEM results where physical damage was observed more on the edges of the tablets than the face of the tablets. Also based on the number of tablet-to-tablet interactions, operating the coating process under thermodynamically wetter processing conditions can result in elevated levels of picking and sticking defects being observed based on the specific tablet design evaluated. The results of these efforts allowed the manufacturing and development team to evaluate improvement opportunities not only in tablet design but also to re-evaluate the thermodynamic design space of the coating operation and the mechanical set up of the coating equipment.
APA, Harvard, Vancouver, ISO, and other styles
4

Nascimento, A., S. R. Castilho, R. M. V. R. Almeida, and A. F. C. Infantosi. "Evaluating pharmaceutical assistance activities in Brazilian hospitals." In 2011 Pan American Health Care Exchanges (PAHCE 2011). IEEE, 2011. http://dx.doi.org/10.1109/pahce.2011.5871863.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Costa, Wanderson, José Rafael Nascimento, Elisa Menendez, et al. "A system to help the teaching of pharmaceutical care." In the 6th Euro American Conference. ACM Press, 2012. http://dx.doi.org/10.1145/2261605.2261620.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Arroyo-Jiménez, María Del Mar, Sara Mínguez, Jose Antonio Carbajal, Lucía Castro-Vázquez, Joaquïn González-Fuentes, and Gema Blázquez-Abellán. "II WORKSHOP OF PHARMACEUTICAL CARE OF PARKINSON'S DISEASE PATIENTS." In 11th annual International Conference of Education, Research and Innovation. IATED, 2018. http://dx.doi.org/10.21125/iceri.2018.1916.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Farida, Yeni, Katarina Puspita, and Zahra Yusvida. "Empirical Antibiotics Study on Pneumonia in Intensive Care Unit." In 1st Muhammadiyah International Conference on Health and Pharmaceutical Development. SCITEPRESS - Science and Technology Publications, 2018. http://dx.doi.org/10.5220/0008239200480053.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Quirós, V. Saavedra, R. Capilla Pueyo, I. Roch Hamelin, A. Medina Carrizo, MA Gómez Mateos, and A. Sánchez Guerrero. "4CPS-255 Expanding the process of pharmaceutical care to the institutionalised patient care unit." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.345.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gruenwald, G., and T. Lee. "164. Glutaraldehyde Exposures after Disinfectant Fogging in Pharmaceutical Aseptic Rooms: Evaluation and Control." In AIHce 1996 - Health Care Industries Papers. AIHA, 1999. http://dx.doi.org/10.3320/1.2764825.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

J., Camellia, Pramestutie H. R., and Hariadini A. L. ""Diarrhea Care Program" as Effective Pediatric Diarrhea Counseling Tool for Pharmacy Practice." In Annual International Conference on Pharmacology and Pharmaceutical Sciences. Global Science & Technology Forum (GSTF), 2014. http://dx.doi.org/10.5176/2345-783x_pharma14.27.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pharmaceutical care"

1

Lira, Giselle Amorim, Júlia de Andrade Brandão, Leticia Anderson, and Ênio José Bassi. Immune checkpoint inhibitors in cancer patients from the perspective of pharmaceutical care: a scoping review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.6.0108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nsibirwa, Derrick, Moses Mulumba, AbdulKharim Muhumuza, and Denis Kibira. BACK TO THE ROOTS? A Brief on Tracing the Evolution of Pharmaceutical Manufacturing in Africa. Afya na Haki, 2023. http://dx.doi.org/10.63010/lj56q.

Full text
Abstract:
African Traditional Medicine (ATM) is one of the oldest forms of health care systems that has stood the test of time. The advent of COVID-19 and other epidemics such as Ebola and Marburg call for urgency for Africa to meet its increasing need and demand for pharmaceutical products and tackle persistent lack of access to essential medicines. The aim of this briefing paper is to highlight the different stages that pharmaceutical manufacturing in Africa has gone through. The brief uses the literature review methodology to highlight the various changes from the pre-colonial period, colonial period and post-colonial or post-independence era. This brief indicates that in pre-colonial African society health problems were taken care of in the household using African Traditional Medicine (ATM). However, the coming of Europeans marked a turning point of this age-long tradition and culture. The introduction of Western medicine and culture undermined and stigmatized the traditional health care system in Africa. Colonial states used both civil and criminal laws to challenge and marginalize most forms of African therapeutics. However, no matter how dominant colonial medical systems became in sub-Saharan Africa, they never entirely usurped traditional forms of healing practices already present. Therefore, medical pluralism became the norm even when colonial services received the lion’s share of resources and protections and set the terms of debate for what constituted acceptable medical practice. In post-independence Africa, concerted efforts were and are being made to recognize traditional medicine as an important aspect of health care delivery system, recognizing the value of African technology, knowledge and culture denied by white rulers during their years in control. In recent decades there has been a resurgence in use of traditional therapeutics coupled with calls for Africa and African states to develop capacities in pharmaceutical manufacturing and integration of traditional medicines to improve access to medicines and health care systems. Ѩ We conclude that Africa needs to transform its traditional and complementary medicines into a frontier for pharmaceutical innovation and production to meet its ever-growing needs for sustainable access to medicines. This will be achieved through targeted investments across the pharmaceutical value chain with emphasis on collaboration across the continent
APA, Harvard, Vancouver, ISO, and other styles
3

Ruxrungtham, Kiat, Vorapot Sapsirisavat, Vorasit Vongsutilers, et al. Pharmaceutical equivalence drugs assessment-I (PEDA-I) : assess the pharmaceutical equivalence of generic antiretrovirals distributed in Thailand : Final report. Chulalongkorn University, 2016. https://doi.org/10.58837/chula.res.2016.30.

Full text
Abstract:
Objectives: Ensuring that medicines meet quality standards is mandatory for ensuring safety and efficacy. There have been occasional reports of substandard generic medicines, especially in resource-limiting settings where policies to control quality may be less rigorous. As HIV treatment in Thailand depends mostly on affordable generic antiretrovirals (ARV), we performed quality assurance testing of several generic ARV available from different sources in Thailand and a source from Vietnam. Methods: We sampled Tenofovir 300 mg, Efavirenz 600 mg and Lopinavir/ritonavir 200/50mg from 10 primary hospitals randomly selected from those participating in the National AIDS Program, 2 non-government organization ARV clinics, and 3 private drug stores. Quality of ARV was analyzed by blinded investigators at the Faculty of Pharmaceutical Science, Chulalongkorn University. The analysis included an identification test for drug molecules, a chemical composition assay to quantitate the active ingredients, a uniformity of mass test and a dissolution test to assess in-vitro drug release. Comparisons were made against the standards described in the WHO international pharmacopeia. Results: A total of 42 batches of ARV from 15 sources were sampled from January – March 2015. Among those generics, 23, 17, 1 and 1 were Thai-made, Indian-made and Chinese-made and Vitenam-made respectively. All sampled products, regardless of manufacturers or sources, met the International Pharmacopeia standards for composition assay, mass uniformity and dissolution. Although local regulations restrict ARV supply to hospitals and clinics, samples of ARV could be bought from private drug stores even without formal prescription. Conclusion: Sampled generic ARVs distributed within Thailand and 1 Vietnamese pharmacy showed consistent quality. However some products were illegally supplied without prescription, highlighting the importance of dispensing ARV for treatment or prevention in facilities where continuity along the HIV treatment and care cascade is available.
APA, Harvard, Vancouver, ISO, and other styles
4

Zhong, Lirong, Alexandre V. Mitroshkov, and Tyler J. Gilmore. Analysis of Pharmaceutical and Personal Care Compounds in Wastewater Sludge and Aqueous Samples using GC-MS/MS. Office of Scientific and Technical Information (OSTI), 2016. http://dx.doi.org/10.2172/1242343.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mitroshkov, Alexandre V., Lirong Zhong, and Linda M. P. Thomas. Analysis of Perfluorinated, Pharmaceutical, Personal Care Compounds and Heavy Metals in Waste Water Sludge using GC-MS/MS and Multicollector ICP-MS. Office of Scientific and Technical Information (OSTI), 2019. http://dx.doi.org/10.2172/1494304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Callaghan, Timothy H., Alva O. Ferdinand, Marvellous Akinlotan, et al. Healthy People 2020 Progress for Leading Causes of Death in Rural and Urban America: A Chartbook. Southwest Rural Health Research Center, Texas A&M School of Public Health, 2020. http://dx.doi.org/10.21423/1969.1/201250.

Full text
Abstract:
Rural Americans have historically faced significant challenges in accessing healthcare and preventive healthcare services, including ambulatory care, dental care, emergency services, and pharmaceutical services. Rural Americans are more likely to die from conditions generally considered self-manageable or preventable. This study examines rural versus urban differences in how the U.S. is meeting the Healthy People 2020 mortality objectives for many of the leading causes of death. Our analyses use national vital statistics mortality data available through the Centers for Disease Control and Prevention's Wonder website. Overall, our findings indicate rural America is lagging behind urban America in achieving these objectives. Furthermore, key findings indicate men have been less likely than women to achieve these objectives, the rural South has seen less progress than other regions toward many of the objectives, and suicide mortality has increased across all levels of rurality.
APA, Harvard, Vancouver, ISO, and other styles
7

Young, Matthew M. Proposed Methods For Estimating Costs Of Mental Health In Canada (2007-2020). Greo Evidence Insights, 2023. http://dx.doi.org/10.33684/2023.002.

Full text
Abstract:
This report presents the results of an investigation by Greo Evidence Insights into how Canadian mental health (MH) costs could be estimated. It begins by conducting a review of studies estimating the costs of MH in Canada since 2010 and examines the various approaches employed. Based on this analysis the next section makes recommendations regarding cost types to include, the granularity of the estimates, and the approach to missing/ incomplete data. The report then recommends a phased approach to estimating the cost of mental health: Phase I describes in detail the data sources and methods to estimate public, direct health care costs associated with general and psychiatric MH-related hospitalizations and emergency room visits and non-hospital-based interventions (i.e., physician costs, pharmaceutical costs, community MH services). Phase II describes methods for estimating social and income support payments and indirect costs. Finally, Phase III describes data sources and methods for estimating private health and lost productivity costs.
APA, Harvard, Vancouver, ISO, and other styles
8

Sentcоv, Valentin, Andrei Reutov, and Vyacheslav Kuzmin. Electronic training manual "Acute poisoning with psychotropic substances". SIB-Expertise, 2024. http://dx.doi.org/10.12731/er0777.29012024.

Full text
Abstract:
The significant variety of properties and wide distribution of opiates and opioids in the modern pharmaceutical industry entail not only positive, but also negative consequences in people's lives. The constant search for new drugs entails the emergence of new substances with psychotropic effects. The widespread use of vinegar essence in the food industry, nitrogen oxides in agriculture, and the frequent appearance of carbon disulfide in everyday life create an increased risk to public health. Positional compression syndrome very often accompanies poisoning with psychotropic substances, which leads to a high risk of disability for victims or even death. This electronic educational resourse consists of seven theoretical educational modules: opioid poisoning, acute psychostimulant poisoning, vinegar essence poisoning, acute carbon monoxide poisoning, acute nitrogen oxide poisoning, acute hydrogen sulfide and carbon disulfide poisoning, positional compression syndrome. The theoretical block of modules is presented by presentations, the text of lectures with illustrations. Control classes in the form of test control accompany each theoretical module. After studying all modules, the student passes the final test control. Mastering the electronic educational resourse will ensure a high level of readiness to provide specialized toxicological care by doctors of various specialties.
APA, Harvard, Vancouver, ISO, and other styles
9

Lucarelli, Claudio, Sean Nicholson, and Minjae Song. Bundling Among Rivals: A Case of Pharmaceutical Cocktails. National Bureau of Economic Research, 2010. http://dx.doi.org/10.3386/w16321.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Huber, Sandra, Mikael Remberger, Arntraut Goetsch, et al. Pharmaceuticals and additives in personal care products as environmental pollutants. Nordic Council of Ministers, 2013. http://dx.doi.org/10.6027/tn2013-541.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical care' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography